YIH
CMPX icon

Y-Intercept (HK)’s Compass Therapeutics CMPX Stock Holding History

Y-Intercept (HK)’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-828,879
Closed -$4.38M – 1776
2026
Q1 		$4.38M Buy
828,879
+366,713
+79% +$2.12M 0.08% 375
2025
Q4 		$2.48M Buy
+462,166
New +$2.13M 0.06% 510

Other funds holding CMPX

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
WAP
Wealthcare Advisory Partners West Chester, Pennsylvania $5.27B AUM 22.23% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
IFG
Independent Financial Group San Diego, California $5.35B AUM 43.78% 1-Year Est. Return
WCP
Wealthcare Capital Partners West Chester, Pennsylvania $242M AUM 18.96% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Y-Intercept (HK)'s CMPX Position: Q2 2026 in Review

Y-Intercept (HK) sold out of Compass Therapeutics (CMPX) in Q2 2026, closing a stake of 828,879 shares — an estimated $4.38M sold.

Y-Intercept (HK) first reported a position in CMPX in Q4 2025 and held it in 2 quarters. The position peaked at $4.38M in Q1 2026. 9 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Y-Intercept (HK) reported no remaining Compass Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Y-Intercept (HK) sold 828,879 Compass Therapeutics shares in Q2 2026, an estimated $4.38M.
  • Y-Intercept (HK) first reported a position in Compass Therapeutics in Q4 2025 and held it in 2 quarters.
  • Y-Intercept (HK)'s Compass Therapeutics position peaked at $4.38M in Q1 2026.
  • 9 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.